Novavax (UK) Today
| 0A3S Stock | 11.90 3.06 34.62% |
Performance4 of 100
| Odds Of DistressOver 61
|
Novavax is selling for under 11.90 as of the 29th of November 2024; that is 34.62% up since the beginning of the trading day. The stock's lowest day price was 9.81. Novavax has more than 61 % chance of experiencing financial distress in the next few years of operation. It also did not have a very good performance during the last 90 trading days. Equity ratings for Novavax are calculated daily based on our scoring framework. The performance scores are derived for the period starting the 30th of October 2024 and ending today, the 29th of November 2024. Click here to learn more.
Business Domain Commercial & Professional Services | Classification Industrials |
Novavax is entity of United Kingdom. It is traded as Stock on LSE exchange. More on Novavax
Moving against Novavax Stock
Follow Valuation Profit Patterns Odds of Bankruptcy
Check how we calculate scores
Novavax Stock Highlights
Most reasonable investors view market volatility as an opportunity to invest at a favorable price or to sell short against a bearish trend. Novavax's investment highlights are automatically generated signals that are significant enough to either complement your investing judgment regarding Novavax or challenge it. These highlights can help you better understand the position you are entering and avoid costly mistakes.
| CEO Pres | Stanley Erck |
| Business Concentration | Environmental & Facilities Services, Commercial & Professional Services, Industrials, Industrials, Commercial Services & Supplies, Commercial & Professional Services, Industrials (View all Sectors) |
Novavax (0A3S) is traded on London Exchange in UK and employs 1,543 people. Novavax is listed under Environmental & Facilities Services category by Fama And French industry classification. The company operates under Commercial Services & Supplies sector and is part of Industrials industry.
Novavax generates negative cash flow from operations
Check Novavax Probability Of Bankruptcy
Ownership AllocationOver half of Novavax's outstanding shares are owned by institutional investors. These institutional investors are typically referred to as corporate investors that shop for positions in a given instrument to benefit from reduced trade commissions. Consequently, these institutions are subject to different rules and regulations than regular investors in Novavax. Please watch out for any change in the institutional holdings of Novavax as this could mean something significant has changed or is about to change at the company.
Check Novavax Ownership Details
Novavax Risk Profiles
Although Novavax's alpha and beta are two of the key measurements used to evaluate Novavax's performance over the market, the standard measures of volatility play an important role as well.
| Mean Deviation | 7.14 | |||
| Semi Deviation | 8.67 | |||
| Standard Deviation | 12.77 | |||
| Variance | 163.19 |
Novavax Stock Against Markets
Be your own money manager
Our tools can tell you how much better you can do entering a position in Novavax without increasing your portfolio risk or giving up the expected return. As an individual investor, you need to find a reliable way to track all your investment portfolios. However, your requirements will often be based on how much of the process you decide to do yourself. In addition to allowing all investors analytical transparency into all their portfolios, our tools can evaluate risk-adjusted returns of your individual positions relative to your overall portfolio.Did you try this?
Run Volatility Analysis Now
Volatility AnalysisGet historical volatility and risk analysis based on latest market data |
| All Next | Launch Module |
Novavax Corporate Management
Elected by the shareholders, the Novavax's board of directors comprises two types of representatives: Novavax inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Novavax. The board's role is to monitor Novavax's management team and ensure that shareholders' interests are well served. Novavax's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Novavax's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Mark Casey | Chief VP | Profile | |
| JD Esq | Senior Officer | Profile | |
| Robert MD | Senior Officer | Profile | |
| Ian Watkins | Executive Officer | Profile |
Additional Tools for Novavax Stock Analysis
When running Novavax's price analysis, check to measure Novavax's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Novavax is operating at the current time. Most of Novavax's value examination focuses on studying past and present price action to predict the probability of Novavax's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Novavax's price. Additionally, you may evaluate how the addition of Novavax to your portfolios can decrease your overall portfolio volatility.